Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Am J Hypertens. 2018 Jan 12;31(2):139-149. doi: 10.1093/ajh/hpx154.
Renovascular disease (RVD) remains a major cause of secondary and treatment-resistant hypertension. Most cases are related either to fibromuscular or atherosclerotic lesions, but a variety of other causes including arterial dissection, stent occlusion, and embolic disease can produce the same syndrome. Recent studies emphasize the kidney's tolerance to moderate flow reduction during antihypertensive drug therapy and the relative safety of medical therapy to control blood pressure. Several prospective trials in moderate RVD fail to identify major benefits from endovascular revascularization for moderate atherosclerotic disease. However, high-risk and progressive renovascular syndromes are recognized to be relatively refractory to medical therapy only and respond better to combining renal revascularization with ongoing medical therapy. Clinicians caring for complex hypertension should be familiar with pathogenic pathways, imaging techniques, and a rational approach to managing renovascular hypertension in the current era.
肾血管疾病(RVD)仍然是继发性和治疗抵抗性高血压的主要原因。大多数病例与纤维肌性或动脉粥样硬化性病变有关,但多种其他原因,包括动脉夹层、支架阻塞和栓塞性疾病,都可能产生相同的综合征。最近的研究强调了肾脏在降压药物治疗期间对适度血流减少的耐受性,以及药物治疗控制血压的相对安全性。几项中度 RVD 的前瞻性试验未能确定血管内血运重建对中度动脉粥样硬化性疾病的主要益处。然而,高危和进行性肾血管综合征被认为仅对药物治疗相对难治,通过将肾血运重建与持续的药物治疗相结合,这些综合征的反应更好。治疗复杂高血压的临床医生应该熟悉发病途径、成像技术以及在当前时代管理肾血管性高血压的合理方法。